Clinical characteristics of patients with COVID-19 depending on the treatment received and the presence of type 2 diabetes mellitus

BACKGROUND. Type 2 diabetes mellitus (T2DM) is an independent risk factor for adverse clinical outcomes in patients with Covid-19. There is currently insufficient data evaluating the efficacy and safety of drugs for the treatment of COVID-19, especially in patients with T2DM.AIM. The aim of study wa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	K. G. Lobanova, T. Y. Demidova, S. N. Perekhodov, M. B. Antsiferov
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2021
Materias:	covid-19 type 2 diabetes mellitus hydroxychloroquine antibacterial therapy antiviral therapy tocilizumab anticoagulant therapy mortality Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/29d10e5a50dc4997bfee9c462bc4d108
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:29d10e5a50dc4997bfee9c462bc4d108
record_format	dspace
spelling	oai:doaj.org-article:29d10e5a50dc4997bfee9c462bc4d1082021-11-14T09:00:23ZClinical characteristics of patients with COVID-19 depending on the treatment received and the presence of type 2 diabetes mellitus2072-03512072-037810.14341/DM12764https://doaj.org/article/29d10e5a50dc4997bfee9c462bc4d1082021-09-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/12764https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378BACKGROUND. Type 2 diabetes mellitus (T2DM) is an independent risk factor for adverse clinical outcomes in patients with Covid-19. There is currently insufficient data evaluating the efficacy and safety of drugs for the treatment of COVID-19, especially in patients with T2DM.AIM. The aim of study was to identify an associative relationship between the drugs used and the clinical outcomes of patients with Covid-19 and T2DM.MATERIALS AND METHODS. A retrospective analysis of the clinical outcomes of 1753 patients with COVID-19 who were hospitalized to the redesignated departments of multidisciplinary city clinical hospital in the period from 23.03.2020 to 01.06.2020.RESULTS. The total number of patients is 1,753, of which 311 (17.7%) are patients with DM2. 92.6% of patients received treatment for COVID-19. At the same time, 91.4% of patients received antibiotics (a/b), 61.5% — bronchodilators, 56.6% — injectable anticoagulants (a/c), 45.2% — hydroxychloroquine, 6.3% — antiviral drugs, 5.4% — oral a/c, 4.6% — glucocorticosteroids (GCS), 1.9% — Tocilizumab.Decrease of risk of death among patients with COVID-19 was as the therapy of a/b (OR 0.07, 95% CI 0.05–0.11, p<0.05), bronchodilators (OR 0.12, 95% CI 0.08–0.18, p<0.05) and injection a/c (OR 0.47, 95% CI 0.34–0.67, p<0.05). At the same time, among patients with DM2, compared with patients without DM2, there was a more pronounced reduction in the risk of death during injectable a/c therapy: among patients with DM2, the risk of death decreased by 2.6 times (OR 0.39, 95% CI 0.21–0.73, p<0.05), among patients without DM2 — by 2.1 times (OR 0.47, 95% CI 0.31–0.71, p<0.05). Antiviral drugs was associated with an increased chance of death among patients without DM2 (OR 2.64, 95% CI 1.44–4.86, p<0.05) and among patients with DM2 (OR 4.98, 95% CI 2.11–11.75, p<0.05).CONCLUSION. A significant decrease of the risk of death among patients with COVID-19 was as the therapy of a/b, bronchodilators, and injectable a/c. An increase of the risk of death was observed during therapy with antiviral drugs.K. G. LobanovaT. Y. DemidovaS. N. PerekhodovM. B. AntsiferovEndocrinology Research Centrearticlecovid-19type 2 diabetes mellitushydroxychloroquineantibacterial therapyantiviral therapytocilizumabanticoagulant therapymortalityNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 24, Iss 3, Pp 231-242 (2021)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	covid-19 type 2 diabetes mellitus hydroxychloroquine antibacterial therapy antiviral therapy tocilizumab anticoagulant therapy mortality Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	covid-19 type 2 diabetes mellitus hydroxychloroquine antibacterial therapy antiviral therapy tocilizumab anticoagulant therapy mortality Nutritional diseases. Deficiency diseases RC620-627 K. G. Lobanova T. Y. Demidova S. N. Perekhodov M. B. Antsiferov Clinical characteristics of patients with COVID-19 depending on the treatment received and the presence of type 2 diabetes mellitus
description	BACKGROUND. Type 2 diabetes mellitus (T2DM) is an independent risk factor for adverse clinical outcomes in patients with Covid-19. There is currently insufficient data evaluating the efficacy and safety of drugs for the treatment of COVID-19, especially in patients with T2DM.AIM. The aim of study was to identify an associative relationship between the drugs used and the clinical outcomes of patients with Covid-19 and T2DM.MATERIALS AND METHODS. A retrospective analysis of the clinical outcomes of 1753 patients with COVID-19 who were hospitalized to the redesignated departments of multidisciplinary city clinical hospital in the period from 23.03.2020 to 01.06.2020.RESULTS. The total number of patients is 1,753, of which 311 (17.7%) are patients with DM2. 92.6% of patients received treatment for COVID-19. At the same time, 91.4% of patients received antibiotics (a/b), 61.5% — bronchodilators, 56.6% — injectable anticoagulants (a/c), 45.2% — hydroxychloroquine, 6.3% — antiviral drugs, 5.4% — oral a/c, 4.6% — glucocorticosteroids (GCS), 1.9% — Tocilizumab.Decrease of risk of death among patients with COVID-19 was as the therapy of a/b (OR 0.07, 95% CI 0.05–0.11, p<0.05), bronchodilators (OR 0.12, 95% CI 0.08–0.18, p<0.05) and injection a/c (OR 0.47, 95% CI 0.34–0.67, p<0.05). At the same time, among patients with DM2, compared with patients without DM2, there was a more pronounced reduction in the risk of death during injectable a/c therapy: among patients with DM2, the risk of death decreased by 2.6 times (OR 0.39, 95% CI 0.21–0.73, p<0.05), among patients without DM2 — by 2.1 times (OR 0.47, 95% CI 0.31–0.71, p<0.05). Antiviral drugs was associated with an increased chance of death among patients without DM2 (OR 2.64, 95% CI 1.44–4.86, p<0.05) and among patients with DM2 (OR 4.98, 95% CI 2.11–11.75, p<0.05).CONCLUSION. A significant decrease of the risk of death among patients with COVID-19 was as the therapy of a/b, bronchodilators, and injectable a/c. An increase of the risk of death was observed during therapy with antiviral drugs.
format	article
author	K. G. Lobanova T. Y. Demidova S. N. Perekhodov M. B. Antsiferov
author_facet	K. G. Lobanova T. Y. Demidova S. N. Perekhodov M. B. Antsiferov
author_sort	K. G. Lobanova
title	Clinical characteristics of patients with COVID-19 depending on the treatment received and the presence of type 2 diabetes mellitus
title_short	Clinical characteristics of patients with COVID-19 depending on the treatment received and the presence of type 2 diabetes mellitus
title_full	Clinical characteristics of patients with COVID-19 depending on the treatment received and the presence of type 2 diabetes mellitus
title_fullStr	Clinical characteristics of patients with COVID-19 depending on the treatment received and the presence of type 2 diabetes mellitus
title_full_unstemmed	Clinical characteristics of patients with COVID-19 depending on the treatment received and the presence of type 2 diabetes mellitus
title_sort	clinical characteristics of patients with covid-19 depending on the treatment received and the presence of type 2 diabetes mellitus
publisher	Endocrinology Research Centre
publishDate	2021
url	https://doaj.org/article/29d10e5a50dc4997bfee9c462bc4d108
work_keys_str_mv	AT kglobanova clinicalcharacteristicsofpatientswithcovid19dependingonthetreatmentreceivedandthepresenceoftype2diabetesmellitus AT tydemidova clinicalcharacteristicsofpatientswithcovid19dependingonthetreatmentreceivedandthepresenceoftype2diabetesmellitus AT snperekhodov clinicalcharacteristicsofpatientswithcovid19dependingonthetreatmentreceivedandthepresenceoftype2diabetesmellitus AT mbantsiferov clinicalcharacteristicsofpatientswithcovid19dependingonthetreatmentreceivedandthepresenceoftype2diabetesmellitus
_version_	1718429455823667200

Clinical characteristics of patients with COVID-19 depending on the treatment received and the presence of type 2 diabetes mellitus

Ejemplares similares